Skip to main content

Table 2 Cost-effectiveness results under base case assumptions for screening for HBsAg using laboratory-based assay on a simulated birth cohort of 10,000 live singleton infants

From: Modelling cost-effectiveness of tenofovir for prevention of mother to child transmission of hepatitis B virus (HBV) infection in South Africa

Strategy

Number of infant HBV infectionsa (95% CI)

Cost of deploying the intervention for the whole populationb (n = 10,000) in USD (95% CI)

Incremental cost per infection avoided (USD)

S1

45 (29–121)

0

–

S2

21 (14–69)

94,571 (94,487 - 95,509)

3940 (compared to strategy S1)

S3

28 (19–76)

95,097 (94,980 - 97,244)

Dominatedc (by strategy S2)

  1. a World Health Organisation (WHO) criteria for HBV elimination states an aim of 90% reduction in new chronic infection [1]
  2. b Price of TDF estimated at $2.48/month for strategies S2 and S3 [30]
  3. c S3 is dominated due to both higher costs and higher infections compared to S2
  4. CI = confidence interval
Back to article page

BMC Public Health

ISSN: 1471-2458

Contact us